BIOGENA: Von Invesdor-Finanzierung an die Wiener Börse

Table of contents

BIOGENA • Investment story • Direct digital investment

BIOGENA investment story

A family business becomes a health group. What began for BIOGENA as a family-run micronutrient company is today a health group with more than 120 million euros in revenue.

BIOGENA investment story illustration

Since 2015, many investors have accompanied this journey through Invesdor. Since then, BIOGENA has carried out 16 financing rounds via Invesdor. In total, more than 17 million euros in growth capital flowed into the company. BIOGENA is now carrying out a share issue and preparing for a listing on the Direct Market Plus (Vienna MTF) of the Vienna Stock Exchange. This makes BIOGENA an example of direct digital investment in a real company that has developed step by step and is now entering the capital market.

Direct digital investment: the role of Invesdor investors

Between 2015 and 2022, BIOGENA carried out a total of 16 financing rounds via Invesdor. During this period, investors provided more than 17 million euros in growth capital through Invesdor.

This path is characterized by:

Long-term partnership

BIOGENA did not choose this form of financing only once, but repeatedly, adapted to each respective growth phase.

Direct participation for many instead of a few

Private and smaller professional investors were able to participate at an early stage, with amounts suited to their personal situation. Over the years, this created a broad circle of supporters.

Strong European roots

A significant share of the investments came from Germany, Austria and other European countries — the same markets in which BIOGENA is also gaining customers. Since 2015, around 2,100 investors have invested in BIOGENA through Invesdor. On average, investments amounted to around 7,300 euros per person. Depending on the round, the interest rates of the individual bonds ranged from 3.75% to 6.00% per year. All investments were repaid to investors on schedule and in full.

For many people in Germany, Austria and other European countries, BIOGENA therefore offered an opportunity to participate directly in a medium-sized health company and follow its development over several years.

BIOGENA key figures illustration

What BIOGENA has achieved so far

The capital market prospectus for the current share issue describes BIOGENA’s starting position with clear figures. For the 2024/2025 financial year, the Biogena Group reports, among other things:

group revenue of around 124.9 million euros
historical EBITDA of around 19.1 million euros
an EBITDA margin of around 15.3 percent
group equity of around 298.9 million euros

BIOGENA offers more than 400 products and works with around 30,000 doctors and therapists. The company serves customers in around 70 countries and has more than half a million registered members in the BIOGENA Club. According to the prospectus, BIOGENA already has a production base designed for a revenue volume of around 500 million euros, which is currently only partially utilized. These figures and structures show a grown company with audited financial statements, international reach and a clear focus on prevention and health.

Why the step onto the stock exchange is a logical one

Against this background, the planned step onto the stock exchange is a logical next step for BIOGENA. An IPO enables further equity capital for growth, for example for internationalization, product development, digitalization and new locations.

It creates additional visibility and trust in a regulated environment.

It enables a broader distribution of ownership, into which existing investors can also place themselves as part of their own decisions. For many years, BIOGENA relied on direct financing via Invesdor. This phase helped expand the production base, broaden the market and strengthen digital channels. The now planned listing on Direct Market Plus of the Vienna Stock Exchange adds the capital market level to this path.

BIOGENA IPO illustration

Context for investors

What investors gain from this now

For people who have already financed BIOGENA through Invesdor, the current development is an important milestone. They can see that a family business has become a health group with revenue well above 120 million euros. All BIOGENA investments placed via Invesdor were repaid as agreed.

The company has reached a stage where a stock exchange listing can be carried out.

For investors who are only now getting to know BIOGENA, a different perspective emerges: this is a company with a clear market position and tangible products.

The development of recent years and the current situation are presented transparently in the prospectus.

In both cases, the share issue opens up the opportunity to assess whether and in what form participation in the next stage of the BIOGENA story fits into one’s own investment concept. All information on the current share issue, the use of proceeds and the risks can be found in the capital market prospectus and on BIOGENA’s information page.

Current share issue

Further information on the current BIOGENA share issue

All information on the current share issue, the documents and further details can be found directly on BIOGENA’s information page.

To the BIOGENA share issue

The link opens BIOGENA’s information page in a new tab.

Notes and risks

This text provides information about BIOGENA’s development and the role of Invesdor investors. It does not constitute investment advice and is not an invitation to buy or sell securities. Invesdor does not provide investment brokerage in this context.

The basis for an investment decision is exclusively the published capital market prospectus and the documents of the issuer. Investments in securities and corporate participations involve significant risks, including the complete loss of the capital invested.